#VisualAbstract: Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy, ...
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy, ...
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with ...
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma. 2. ...
1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma. 2. ...
Roxadustat for anemia in patients with kidney disease not receiving dialysis Chronic kidney disease (CKD)-related anemia is associated with significant ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.